Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CREBBP | Q92793 | 5/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | IDO1 | P14902 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 2/20 | 0.32 |
| ▸ | GFER | P55789 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6651992 | 0.83 | GAA (0.44) | CREBBPKMT2AKDM4EBRD4GAA | |
| Hydrochloric Acid SCHEMBL6754094 | 0.82 | GAA (0.43) | CREBBPKMT2AKDM4EBRD4GAA | |
| SCHEMBL5166834 | 0.82 | CREBBP (0.81) | CREBBPKMT2APOLBTP53MAPT | |
| SCHEMBL5169235 | 0.81 | CREBBP (0.76) | CREBBPKMT2APOLBTP53MAPT | |
| SCHEMBL5169227 | 0.80 | CREBBP (0.56) | CREBBPKMT2APOLBTP53MAPT | |
| SCHEMBL5165749 | 0.80 | CREBBP (0.74) | CREBBPKMT2APOLBTP53MAPT | |
| SCHEMBL5166430 | 0.79 | CREBBP (0.64) | CREBBPKMT2APOLBTP53MAPT | |
| SCHEMBL5170207 | 0.78 | CREBBP (0.62) | CREBBPKMT2APOLBTP53MAPT | |
| SCHEMBL20642102 | 0.77 | CREBBP (1.00) | CREBBPKMT2APOLBTP53MAPT | |
| Hydrochloric Acid SCHEMBL5168205 | 0.77 | CREBBP (0.61) | CREBBPKMT2APOLBTP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6849642-B2 | Bicyclic imidazo-3-yl-amine derivatives substituted on the 6-membered ring | GRUENENTHAL GMBH (DE) | 2005-02-01 | — | — | US | claimed |
| US-20040023972-A1 | Use of substituted imidazo[1,2-a]-pyridin-, -pyrimidin-and-pyrazin-3-yl-amine derivatives in the preparation of medicaments for inhibiting NOS | GRUENENTHAL GMBH (DE) | 2004-02-05 | — | — | US | claimed |
| EP-1218380-B1 | BICYCLIC IMIDAZO-3-YL-AMINE DERIVATIVES WHICH ARE SUBSTITUTED ON THE SIXTH RING | GRUENENTHAL GMBH (DE) | 2003-12-17 | — | — | EP | claimed |
| EP-1326613-A1 | USE OF SUBSTITUTED IMIDAZO 1,2-A]PYRIDINE-, IMIDAZO 1,2-A]PYRIMIDINE AND IMIDAZO 1,2-A]PYRAZINE-3-YL-AMINE DERIVATIVES FOR PRODUCING NOS-INHIBITING MEDICAMENTS | Grünenthal GmbH (DE) | 2003-07-16 | — | — | EP | claimed |
| US-20020183327-A1 | Bicyclic imidazo-3-yl-amine derivatives substituted on the 6-membered ring | GRUENENTHAL GMBH. | 2002-12-05 | — | — | US | claimed |
| WO-2002030428-A1 | USE OF SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE-, IMIDAZO[1,2-A]PYRIMIDINE AND IMIDAZO[1,2-A]PYRAZINE-3-YL-AMINE DERIVATIVES FOR PRODUCING NOS-INHIBITING MEDICAMENTS | Grünenthal GmbH (DE) | 2002-04-18 | — | — | WO | claimed |
| EP-1326613-B2 | USE OF SUBSTITUTED IMIDAZO 1,2-A|PYRIDINE-, IMIDAZO ¬1,2-A|PYRIMIDINE AND IMIDAZO ¬1,2-A|PYRAZINE-3-YL-AMINE DERIVATIVES FOR PRODUCING NOS-INHIBITING MEDICAMENTS | GRUENENTHAL GMBH (DE) | 2007-04-18 | — | — | EP | disclosed |
| US-6849642-B2 | Bicyclic imidazo-3-yl-amine derivatives substituted on the 6-membered ring | GRUENENTHAL GMBH (DE) | 2005-02-01 | — | — | US | disclosed |
| EP-1326613-B1 | USE OF SUBSTITUTED IMIDAZO 1,2-A]PYRIDINE-, IMIDAZO [1,2-A]PYRIMIDINE AND IMIDAZO [1,2-A]PYRAZINE-3-YL-AMINE DERIVATIVES FOR PRODUCING NOS-INHIBITING MEDICAMENTS | GRUENENTHAL GMBH (DE) | 2004-06-02 | — | — | EP | disclosed |
| US-20040023972-A1 | Use of substituted imidazo[1,2-a]-pyridin-, -pyrimidin-and-pyrazin-3-yl-amine derivatives in the preparation of medicaments for inhibiting NOS | GRUENENTHAL GMBH (DE) | 2004-02-05 | — | — | US | disclosed |
| EP-1218380-B1 | BICYCLIC IMIDAZO-3-YL-AMINE DERIVATIVES WHICH ARE SUBSTITUTED ON THE SIXTH RING | GRUENENTHAL GMBH (DE) | 2003-12-17 | — | — | EP | disclosed |
| EP-1326613-A1 | USE OF SUBSTITUTED IMIDAZO 1,2-A]PYRIDINE-, IMIDAZO 1,2-A]PYRIMIDINE AND IMIDAZO 1,2-A]PYRAZINE-3-YL-AMINE DERIVATIVES FOR PRODUCING NOS-INHIBITING MEDICAMENTS | Grünenthal GmbH (DE) | 2003-07-16 | — | — | EP | disclosed |
| US-20020183327-A1 | Bicyclic imidazo-3-yl-amine derivatives substituted on the 6-membered ring | GRUENENTHAL GMBH. | 2002-12-05 | — | — | US | disclosed |
| EP-1218380-A2 | BICYCLIC IMIDAZO-3-YL-AMINE DERIVATIVES WHICH ARE SUBSTITUTED ON THE SIXTH RING | Grünenthal GmbH (DE) | 2002-07-03 | — | — | EP | disclosed |
| WO-2002030428-A1 | USE OF SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE-, IMIDAZO[1,2-A]PYRIMIDINE AND IMIDAZO[1,2-A]PYRAZINE-3-YL-AMINE DERIVATIVES FOR PRODUCING NOS-INHIBITING MEDICAMENTS | Grünenthal GmbH (DE) | 2002-04-18 | — | — | WO | disclosed |
| WO-2001027110-A2 | BICYCLIC IMIDAZO-3-YL-AMINE DERIVATIVES WHICH ARE SUBSTITUTED ON THE SIXTH RING | Grünenthal GmbH (DE) | 2001-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020183327-A1 | Bicyclic imidazo-3-yl-amine derivatives substituted on the 6-membered ring | OPRK1, GRIN3A, OPRM1 | CREBBP 1665/4885KMT2A 1060/4885POLB 3830/4885 |
| US-20040023972-A1 | Use of substituted imidazo[1,2-a]-pyridin-, -pyrimidin-and-pyrazin-3-yl-amine derivatives in the preparation of medicaments for inhibiting NOS | NOS1, PTGIS, NOS2 | CREBBP 1065/4885KMT2A 2977/4885POLB 710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.